AR011681A1 - Una composicion liofilizada que comprende trehalosa y liposomas de lipidos en los cuales se ha incorporado un principio biologicamente activo y un procedimiento para la liofilizacion de una composicion que comprende trehalosa y liposomas de lipidos - Google Patents
Una composicion liofilizada que comprende trehalosa y liposomas de lipidos en los cuales se ha incorporado un principio biologicamente activo y un procedimiento para la liofilizacion de una composicion que comprende trehalosa y liposomas de lipidosInfo
- Publication number
- AR011681A1 AR011681A1 ARP980100754A ARP980100754A AR011681A1 AR 011681 A1 AR011681 A1 AR 011681A1 AR P980100754 A ARP980100754 A AR P980100754A AR P980100754 A ARP980100754 A AR P980100754A AR 011681 A1 AR011681 A1 AR 011681A1
- Authority
- AR
- Argentina
- Prior art keywords
- liposomes
- trehalose
- biologically active
- active principle
- composition
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title abstract 9
- 239000000203 mixture Substances 0.000 title abstract 8
- 150000002632 lipids Chemical class 0.000 title abstract 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 title abstract 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 title abstract 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 title abstract 6
- 238000004108 freeze drying Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- -1 1-benzyl-1H-3-indazolyl Chemical group 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 238000001816 cooling Methods 0.000 abstract 2
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 abstract 2
- MTHORRSSURHQPZ-UHFFFAOYSA-N 2-[(1-benzylindazol-3-yl)methoxy]-2-methylpropanoic acid Chemical compound C12=CC=CC=C2C(COC(C)(C)C(O)=O)=NN1CC1=CC=CC=C1 MTHORRSSURHQPZ-UHFFFAOYSA-N 0.000 abstract 1
- 229930105110 Cyclosporin A Natural products 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 abstract 1
- 229950009949 bindarit Drugs 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 238000007710 freezing Methods 0.000 abstract 1
- 230000008014 freezing Effects 0.000 abstract 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 abstract 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 abstract 1
- 125000005456 glyceride group Chemical group 0.000 abstract 1
- 150000002327 glycerophospholipids Chemical class 0.000 abstract 1
- 229960003538 lonidamine Drugs 0.000 abstract 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003987 melatonin Drugs 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 150000003408 sphingolipids Chemical class 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composicion liofilizada que comprende trehalosa y liposomas de lípidos en los cuales se ha incorporado un principio biologicamente activo,donde el principio biologicamente activo es altamente insoluble en agua, la relacion de pesode trehalosa/lípido es </=1,5 y toda la trehalosa se incorporoa la parte externa de los liposomas ya formados antes de la liofilizacion. Preferentemente el principio biologicamente activo, que es altamente insolubleen agua se selecciona delgrupo que comprende ácido 1-[(2,4-diclorofenil)metil] -1H-indazol-3-carboxílico, (Lonidamina), melatonina, ciclosporina A y ácido2-[(1-bencil-1H-3-indazolil)metoxi]-2-metilpropanoico, (Bindarit). De preferencia los lípidos se seleccionandel grup o que comprende fosfoglicéridos,glicéridos, diglicéridos, triglicéridos, fosfolípidos, lípidos de galactosilo y glucosilo, colesterol y sus derivados, esfingolípidos y sus mezclas. Eltamano promedio de los liposomas puede quedarcomprendido entre 5 0 y 250 nm. Un procedimiento para la liofilizacion de una composicion que comprendetrehalosa y liposomas de lípidos, en la cual se ha incorporado un principio biologicamente activo, donde: a) de 0,2 a 1,5 partes en peso detrehalosa seagregan a cada parte en peso de los lípidos de una composicion de liposomas acuosa, en la cual el tamano promedio de los liposomas queda comprendidoentre 50 y 250 nm, comprendiendo dichos liposomas un principio biologicamente activo,el cual es altamet ne insoluble en agua; b) dicha composicion se enfríaa través de la placa de enfriamiento del liofilizador, a una temperatura ubicada entre -5°C y -70°C, a una velocidad de enfriamiento comprendida entre0,5* y 2°C/min; c)una vez que se alcanza la tempertura de congelamiento predeterminada, dicha composicion se mantiene a dicha temperatura, durante
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI000362A IT1289938B1 (it) | 1997-02-20 | 1997-02-20 | Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR011681A1 true AR011681A1 (es) | 2000-08-30 |
Family
ID=11376097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980100754A AR011681A1 (es) | 1997-02-20 | 1998-02-20 | Una composicion liofilizada que comprende trehalosa y liposomas de lipidos en los cuales se ha incorporado un principio biologicamente activo y un procedimiento para la liofilizacion de una composicion que comprende trehalosa y liposomas de lipidos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6319517B1 (es) |
| EP (1) | EP0981332B1 (es) |
| JP (1) | JP4290767B2 (es) |
| KR (1) | KR100496802B1 (es) |
| CN (1) | CN1089581C (es) |
| AR (1) | AR011681A1 (es) |
| AT (1) | ATE285754T1 (es) |
| AU (1) | AU744115B2 (es) |
| BG (1) | BG64580B1 (es) |
| CA (1) | CA2288958C (es) |
| CZ (1) | CZ295998B6 (es) |
| DE (1) | DE69828394T2 (es) |
| EA (1) | EA001637B1 (es) |
| ES (1) | ES2235320T3 (es) |
| GE (1) | GEP20022734B (es) |
| HU (1) | HU225593B1 (es) |
| IL (1) | IL131327A (es) |
| IT (1) | IT1289938B1 (es) |
| PL (1) | PL190628B1 (es) |
| PT (1) | PT981332E (es) |
| SK (1) | SK282931B6 (es) |
| TR (1) | TR199902025T2 (es) |
| UA (1) | UA70296C2 (es) |
| WO (1) | WO1998036736A1 (es) |
| ZA (1) | ZA981352B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60012932T2 (de) * | 1999-06-23 | 2005-08-18 | Cornell Research Foundation, Inc. | Entwässerung/rehydratisierung von markierten liposomen auf einer prüfeinrichtung |
| US6576460B1 (en) | 1999-10-28 | 2003-06-10 | Cornell Research Foundation, Inc. | Filtration-detection device and method of use |
| MXPA05007572A (es) * | 2003-01-17 | 2005-11-17 | Threshold Pharmaceuticals Inc | Tratamiento de hiperplasia prostatica benigna. |
| CA2603084A1 (en) | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
| WO2008036979A2 (en) * | 2006-09-22 | 2008-03-27 | Guilford F Timothy | Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non-histamine related inflammatory skin changes |
| CN101049504B (zh) * | 2007-04-05 | 2010-05-19 | 广州立恩生物科技有限公司 | 一种脂质体药物载体及其制备方法 |
| US9446147B2 (en) | 2011-02-24 | 2016-09-20 | The Ohio State University | Membrane stabilizing compositions and methods |
| EP3572071A1 (en) | 2011-10-21 | 2019-11-27 | Jazz Pharmaceuticals Research LLC | Lyophilized liposomes |
| US8999292B2 (en) | 2012-05-01 | 2015-04-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| WO2014035206A2 (ko) * | 2012-08-31 | 2014-03-06 | 중앙대학교 산학협력단 | 색전용 마이크로스피어의 제조방법 및 약물 함유 나노수송체가 결합된 마이크로스피어의 제조방법 |
| US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
| US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| KR102646145B1 (ko) | 2018-05-31 | 2024-03-11 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물 |
| IL279760B2 (en) * | 2018-06-27 | 2025-10-01 | Breath Therapeutics Gmbh | Pharmaceutical preparations in lyophilized form |
| JP7526103B2 (ja) * | 2018-06-27 | 2024-07-31 | ブレス テラポイティクス ゲーエムベーハー | 大環状免疫抑制剤を含む吸入用組成物 |
| CN112261871B (zh) * | 2018-07-28 | 2022-05-17 | 韩国外泌体生技有限公司 | 用于使外排体冻干的方法 |
| KR102163806B1 (ko) | 2018-07-30 | 2020-10-07 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물 |
| EA202092892A1 (ru) | 2018-12-04 | 2021-05-27 | Брес Терапьютикс Гмбх | Ингаляционные композиции, содержащие макроциклические иммуносупрессанты |
| US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
| US11753382B2 (en) | 2019-06-25 | 2023-09-12 | Translatum Medicus Inc. | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives |
| CN111358955B (zh) * | 2020-04-01 | 2023-05-02 | 重庆理工大学 | 一种用于治疗脂质代谢疾病的炎症靶向的宾达利纳米粒、制备方法及其应用 |
| JP7508359B2 (ja) * | 2020-12-11 | 2024-07-01 | 株式会社東芝 | 脂質粒子の製造方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1173360A (en) * | 1979-06-22 | 1984-08-28 | Jurg Schrank | Pharmaceutical preparations |
| FR2542749B1 (fr) * | 1983-03-18 | 1985-07-12 | Beghin Say Sa | Copolymere allyloligosaccharide-acrylique salifie, procede de preparation du copolymere et application comme super-absorbant |
| US4857319A (en) * | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
| US4963362A (en) * | 1987-08-07 | 1990-10-16 | Regents Of The University Of Minnesota | Freeze-dried liposome mixture containing cyclosporin |
| US5683714A (en) * | 1991-04-19 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Liposomal cyclosporin pharmaceutical formulation |
| US5817336A (en) * | 1993-04-02 | 1998-10-06 | Orion-Yhtyma Oy | Composition containing selegiline |
| GB9320668D0 (en) * | 1993-10-07 | 1993-11-24 | Secr Defence | Liposomes containing particulare materials |
| DK0678017T3 (da) * | 1993-11-05 | 1998-10-19 | Amgen Inc | Liposomfremstilling og materialeindkapslingsfremgangsmåde |
-
1997
- 1997-02-20 IT IT97MI000362A patent/IT1289938B1/it active IP Right Grant
-
1998
- 1998-02-12 AU AU64969/98A patent/AU744115B2/en not_active Ceased
- 1998-02-12 DE DE69828394T patent/DE69828394T2/de not_active Expired - Lifetime
- 1998-02-12 ES ES98910659T patent/ES2235320T3/es not_active Expired - Lifetime
- 1998-02-12 EP EP98910659A patent/EP0981332B1/en not_active Expired - Lifetime
- 1998-02-12 CN CN98802737A patent/CN1089581C/zh not_active Expired - Fee Related
- 1998-02-12 EA EA199900751A patent/EA001637B1/ru not_active IP Right Cessation
- 1998-02-12 CZ CZ19992925A patent/CZ295998B6/cs not_active IP Right Cessation
- 1998-02-12 PL PL98335207A patent/PL190628B1/pl unknown
- 1998-02-12 KR KR10-1999-7007538A patent/KR100496802B1/ko not_active Expired - Fee Related
- 1998-02-12 IL IL13132798A patent/IL131327A/en not_active IP Right Cessation
- 1998-02-12 TR TR1999/02025T patent/TR199902025T2/xx unknown
- 1998-02-12 AT AT98910659T patent/ATE285754T1/de active
- 1998-02-12 HU HU0001464A patent/HU225593B1/hu not_active IP Right Cessation
- 1998-02-12 US US09/367,715 patent/US6319517B1/en not_active Expired - Lifetime
- 1998-02-12 GE GEAP19984991A patent/GEP20022734B/en unknown
- 1998-02-12 CA CA002288958A patent/CA2288958C/en not_active Expired - Fee Related
- 1998-02-12 PT PT98910659T patent/PT981332E/pt unknown
- 1998-02-12 WO PCT/EP1998/000817 patent/WO1998036736A1/en not_active Ceased
- 1998-02-12 SK SK1110-99A patent/SK282931B6/sk not_active IP Right Cessation
- 1998-02-12 JP JP53622898A patent/JP4290767B2/ja not_active Expired - Fee Related
- 1998-02-18 ZA ZA981352A patent/ZA981352B/xx unknown
- 1998-02-20 AR ARP980100754A patent/AR011681A1/es active IP Right Grant
- 1998-12-02 UA UA99095150A patent/UA70296C2/uk unknown
-
1999
- 1999-09-16 BG BG103738A patent/BG64580B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR011681A1 (es) | Una composicion liofilizada que comprende trehalosa y liposomas de lipidos en los cuales se ha incorporado un principio biologicamente activo y un procedimiento para la liofilizacion de una composicion que comprende trehalosa y liposomas de lipidos | |
| US6759057B1 (en) | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs | |
| ES2221066T3 (es) | Utilizacion de inhibidores de no-sintasa y de eliminadores de formas reactivas del oxigeno para el tratamiento de la isquemia. | |
| US5985854A (en) | Prodrugs with enhanced penetration into cells | |
| US6495532B1 (en) | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof | |
| AR023971A1 (es) | Derivados de 4,5,6,7-tetrahidroindazol, procedimiento para la preparacion de los mismos y su utilizacion como agentes antitumorales | |
| CO5130023A1 (es) | Administracion de agente activo en polvo seco agente activo y un inhibidor del crecimiento higroscopico | |
| ES2186792T3 (es) | Metodos de fabricar liposomas que contienen fotosensibilizantes hidro-monobenzoporfirinicos. | |
| ES2280355T3 (es) | Sistema de administracion de medicamentos basados en lipidos para su utilizacion en la piel. | |
| ATE286718T1 (de) | Temperatursensitive liposomale formulierung | |
| MX9606521A (es) | Inhibidores de trombina novedosos, preparacion y uso de los mismos. | |
| ES2232302B1 (es) | Myo-inositol hexafosfato para uso topico. | |
| CA2486909A1 (en) | Compositions and method for transmucosal drug delivery and cryoprotection | |
| PT93884B (pt) | Processo de preparacao de uma composicao farmaceutica a base de acido 5-amino-salicilico, sob a forma de uma espuma | |
| CR6643A (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| AR031067A1 (es) | Un sachet; una tableta y un polvo efervescente de administracion oral para prevenir y tratar disfunciones sexuales y el uso de l-arginina y/o yohimbina y/o una sal farmaceuticamente aceptable de la misma. | |
| AR042053A1 (es) | Hidroxiindoles nuevos, su uso como inhibidores de la fosfodiestrasa - 4, y procesos para su preparacion | |
| US20030235610A1 (en) | Liposomes containing biologically active compounds | |
| ES2171923T3 (es) | Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos. | |
| MX9301197A (es) | Derivados de indol. | |
| CO4940406A1 (es) | Composiciones de paracetamol de accion rapida | |
| AR033151A1 (es) | Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares | |
| ES2716806T3 (es) | Formulación Oftálmica | |
| Hartner et al. | ATP‐loaded liposomes for treatment of myocardial ischemia | |
| PA8613001A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FG | Grant, registration |